RLMD - Relmada Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
583.88M
Enterprise Value 3
414.41M
Trailing P/E
N/A
Forward P/E 1
N/A
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
N/A
Price/Book (mrq)
68.34
Enterprise Value/Revenue 3
N/A
Enterprise Value/EBITDA 6
-32.45

Trading Information

Stock Price History

Beta (5Y Monthly) 0.06
52-Week Change 3627.78%
S&P500 52-Week Change 325.98%
52 Week High 348.00
52 Week Low 34.60
50-Day Moving Average 339.31
200-Day Moving Average 320.58

Share Statistics

Avg Vol (3 month) 3166.64k
Avg Vol (10 day) 3113.41k
Shares Outstanding 514.22M
Float 7.72M
% Held by Insiders 110.79%
% Held by Institutions 110.81%
Shares Short (Dec 30, 2019) 4929.69k
Short Ratio (Dec 30, 2019) 43.16
Short % of Float (Dec 30, 2019) 49.69%
Short % of Shares Outstanding (Dec 30, 2019) 46.54%
Shares Short (prior month Nov 28, 2019) 4380.11k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:4
Last Split Date 3Sep 29, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun 29, 2019
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-158.56%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -12.77M
Net Income Avi to Common (ttm)-17.61M
Diluted EPS (ttm)-2.21
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)7.85M
Total Cash Per Share (mrq)0.76
Total Debt (mrq)255.93k
Total Debt/Equity (mrq)4.28
Current Ratio (mrq)3.27
Book Value Per Share (mrq)0.60

Cash Flow Statement

Operating Cash Flow (ttm)-11.36M
Levered Free Cash Flow (ttm)-10.79M